---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-300141"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:23:13.098106+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phoenix Biotech Acquisition Corp. and Intrinsic Medicine mutually terminate business combination agreement

## Summary
- Business combination agreement terminated on December 6, 2022 due to current market conditions.
- No termination fee or other payment due from any party as a result of the termination.
- Sponsor support agreement and intrinsic support agreements automatically terminated.
- PBAX CEO Chris Ehrlich expressed continued optimism about Intrinsic's platform.

## SEC filing metadata
- accession: 0001193125-22-300141
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/d421267d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-300141
- JSON: https://secwatch.observer/filing/0001193125-22-300141.json
- Plain text: https://secwatch.observer/filing/0001193125-22-300141.txt

## Key facts
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. terminated Sponsor Support Agreement with Phoenix Biotech Sponsor, LLC (effective 2022-12-06).
  - Action: termination
  - Agreement: asset purchase
  - Counterparty: Phoenix Biotech Sponsor, LLC
  - Effective: 2022-12-06
  source text: The Sponsor Support Agreement, dated as of October 30, 2022 (the “ Sponsor Support Agreement ”), by and among the Company, Intrinsic, Phoenix Biotech Sponsor, LLC, a Delaware limited liability company, and each of the Company’s officers and directors, automatically terminated in accordance with its terms upon the termination of the Business Combination Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. terminated Business Combination Agreement with Intrinsic Medicine, Inc. (effective 2022-12-06).
  - Action: termination
  - Agreement: merger
  - Counterparty: Intrinsic Medicine, Inc.
  - Effective: 2022-12-06
  source text: On December 6, 2022 (the “ Termination Date ”), the Company and Intrinsic entered into a Termination Agreement (the “ Termination Agreement ”), a copy of which is filed as Exhibit 2.1 hereto, which among other things provides for the mutual termination of the Business Combination Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. terminated Intrinsic Support Agreements with certain Intrinsic stockholders (effective 2022-12-06).
  - Action: termination
  - Agreement: asset purchase
  - Counterparty: certain Intrinsic stockholders
  - Effective: 2022-12-06
  source text: The support agreements, dated as of October 30, 2022 (the “ Intrinsic Support Agreements ”), by and among the Company, Intrinsic and certain Intrinsic stockholders, automatically terminated in accordance with their terms upon the termination of the Business Combination Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000119312522300141/0001193125-22-300141-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.